Paul Anthony Williams - 09 Jan 2023 Form 3 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
SVP, Products Business
Signature
/s/ Jennifer Lynne Fox, Attorney-in-fact
Issuer symbol
EBS
Transactions as of
09 Jan 2023
Net transactions value
$0
Form type
3
Filing time
18 Jan 2023, 10:39:35 UTC
Next filing
27 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding EBS Common Stock 9,376 09 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EBS Employee Stock Options (Right to Buy) 09 Jan 2023 Common Stock 1,769 $93.49 Direct F2
holding EBS Employee Stock Options (Right to Buy) 09 Jan 2023 Common Stock 1,693 $59.07 Direct F2
holding EBS Employee Stock Options (Right to Buy) 09 Jan 2023 Common Stock 7,613 $41.38 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of 1,581 shares and 7,795 unvested RSUs granted from the Emergent Stock Incentive Plan. Each RSU represents a right to receive one share of common stock. The RSUs vest in three equal installments annually on the day prior to the anniversary date of the grant.
F2 Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

Remarks:

Exhibit list: Ex 24.1 - Power of Attorney